Unique ID issued by UMIN | UMIN000039867 |
---|---|
Receipt number | R000045465 |
Scientific Title | The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study) |
Date of disclosure of the study information | 2020/03/19 |
Last modified on | 2022/12/06 12:16:39 |
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
Japan |
Prostate cancer
Urology |
Malignancy
NO
To investigate the association of baseline frailty and quality of life in prostate cancer
Safety,Efficacy
Primary outcomes: the association of baseline frailty and quality of life.
Secondary outcomes: effect of frailty and QOL on overall survival in metastatic prostate cancer
Observational
20 | years-old | <= |
100 | years-old | > |
Male
Patients with prostate cancer who can evaluate frailty
Patients with prostate cancer who cannot evaluate frailty
400
1st name | Shingo |
Middle name | Hatakeyama |
Last name | Hatakeyama |
Dept. of Urology, Hirosaki University Graduate School of Medicine
Urology
036-8562
Hirosaki
0172395091
shingorilla2@gmail.com
1st name | Shingo |
Middle name | |
Last name | Hatakeyama |
Dept. of Urology, Hirosaki University Graduate School of Medicine
Urology
036-8562
Hirosaki
0172395091
shingorilla2@gmail.com
Dept. of Urology, Hirosaki University Graduate School of Medicine
Dept. of Urology, Hirosaki University Graduate School of Medicine
Government offices of other countries
Hirosaki University Graduate School of Medicine
5 Zaifu-chou
+81172395091
rinri@hirosaki-u.ac.jp
NO
2020 | Year | 03 | Month | 19 | Day |
https://pubmed.ncbi.nlm.nih.gov/33079283/
Published
https://pubmed.ncbi.nlm.nih.gov/33079283/
369
The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.
2022 | Year | 12 | Month | 06 | Day |
The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown.
We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool
none
and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8<=14) on worse QOL.
Completed
2017 | Year | 01 | Month | 06 | Day |
2017 | Year | 01 | Month | 06 | Day |
2017 | Year | 01 | Month | 07 | Day |
2022 | Year | 12 | Month | 05 | Day |
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-UC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
In the PC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments (FRAPC study), the effect of frailty on safety and oncological outcomes 2) between the radical prostatectomy and radiation therapy in patients with localized prostate cancer (FRART-PC study), 3) among the patients with metastatic PC (FRAM-PC study), 4) the association of baseline frailty and quality of life (FRAQ-PC study), and 5) the association of baseline frailty and postoperative pain (FRAP study).
In the RCC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) in the patients with radical or partial nephrectomy (FRARN study), 2) between in the mRCC patients with molecular targeted therapy and/or immunotherapy(FRARMT study), and 4) the association of baseline frailty and quality of life (FRAQ-RCC). Also, we planned to estimate the gap between chronological and biological age using frailty (FRAGE-GAP study).
2020 | Year | 03 | Month | 18 | Day |
2022 | Year | 12 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045465
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |